Clinical trials
Ovarian cancer clinical trials
Cancer that starts in the ovaries, often found at a later stage. We’re tracking 599 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT06395844RecruitingPhase 1/Phase 2
NK cell therapy for advanced ovarian cancer
This trial tests a new therapy that uses your own natural killer (NK) cells, modified to better fight cancer and injected directly into your abdomen. It's for people with advanced ovarian cancer who cannot have surgery or whose tumor cannot be fully removed.
Hefei, AnhuiAges 18–70 - NCT05842629Recruiting
Better ways to diagnose ovarian cancer
This study focuses on improving diagnosis of ovarian cancer. If you have an abnormal mass seen on ultrasound near the ovaries, the researchers may evaluate how best to identify whether it could be ovarian cancer.
AarhusAges Any age - NCT06216496Recruiting
Amino acid changes in advanced ovarian cancer
This study looks at how ovarian cancer changes the body's use of amino acids, which are building blocks of proteins. It may help find new ways to monitor or treat the disease.
La TroncheAges 40–70 - NCT03755739RecruitingPhase 2/Phase 3
Checkpoint cancer drug given into or near tumors
This trial studies whether giving immunotherapy “checkpoint inhibitor” medicine directly into the tumor area (and/or the artery feeding it), along with a chemotherapy-style drug, can work better for advanced solid tumors. It aims to boost the immune system’s ability to attack cancer while still being safe for people with measurable tumors.
Guanzhou, GuangdongAges 18 years+ - NCT07822646RecruitingPhase 3
Study of a new treatment for advanced ovarian cancer
This study tests a new combination treatment for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after at least two prior treatments. The aim is to see if this treatment can help shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07821879Recruiting
Early ovarian cancer detection via cervical smear testing
This study looks at whether a standard cervical smear test can help find ovarian cancer earlier. The test searches for genetic changes linked to high-grade serous ovarian cancer in cells collected from the cervix, possibly enabling earlier diagnosis.
ToulouseAges 18 years+ - NCT06394492RecruitingPhase 3
Testing a new drug for platinum-resistant ovarian cancer
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07776691RecruitingPhase 3
Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07783022Recruiting
Real-world study of niraparib for ovarian cancer after initial treatment
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
ShanghaiAges 18 years+ - NCT07782164Recruiting
Irreversible electroporation for recurrent pelvic tumors
This study tests a new technique called irreversible electroporation (IRE) for treating pelvic tumors that have returned despite earlier treatment. IRE uses electrical pulses to destroy cancer cells without surgery, offering a potential option when other local treatments like surgery or radiation are not suitable.
Amsterdam, North HollandAges 18 years+ - NCT06014190RecruitingPhase 2
HS-20089 for ovarian and endometrial cancer
This trial tests a new medication (HS-20089) for people with ovarian or endometrial cancer that has come back or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Hefei, AnfeiAges 18 years+ - NCT04665635Recruiting
Ovarian cancer surgery: bowel shaving vs bowel resection
This trial compares two surgical options for ovarian cancer that involves the rectosigmoid bowel wall: removing a segment (resection) versus shaving only the involved layer (tumor shaving). It may help find which approach is safer and better for people whose cancer has spread to the outer bowel layers.
AdanaAges 18 years+ - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Orlando, FloridaAges 18 years+ - NCT07733505RecruitingPhase 1
Heated chemotherapy for older women with advanced ovarian cancer
This trial tests a new way to give heated chemotherapy directly into the abdomen during surgery for women aged 70 and older with advanced ovarian cancer. It aims to find a gentler treatment option that may still be effective for those who are more frail.
OdenseAges 70 years+ - NCT07736937RecruitingPhase 1/Phase 2
Study of TUB-040 with Standard Drugs for Ovarian Cancer
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07718854RecruitingPhase 2
Study of two drugs for advanced ovarian clear cell cancer
This study tests two investigational drugs, alone or together, for advanced ovarian clear cell cancer that has not responded to usual treatments. The goal is to see if these drugs help shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT07714668RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06640348Recruiting
New blood test for ovarian cancer screening
This study uses a special blood test (SERS) to find tiny signs of ovarian cancer in the blood. It may help diagnose ovarian cancer earlier or more accurately.
Hefei, AnhuiAges 18–70 - NCT04921527RecruitingPhase 3
Chiauranib with weekly paclitaxel for tough ovarian cancer
This Phase 3 trial tests whether chiauranib combined with weekly paclitaxel can shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to platinum chemotherapy. It is designed for people who have limited treatment options after platinum-resistant or platinum-refractory disease.
Shanghai, ChinaAges 18–70 - NCT07693894Recruiting
Ovarian cancer biomarker blood test study
This study is testing new blood tests that might help detect ovarian cancer earlier by looking for specific markers. It involves people with suspected ovarian cancer and healthy volunteers, and aims to improve how we diagnose the disease.
PragueAges 35 years+ - NCT06660511RecruitingEarly Phase 1
Combination therapy for HER2-positive platinum-resistant ovarian cancer
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT07665515RecruitingPhase 1
Testing a cancer vaccine in maintenance for advanced ovarian cancer
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
CambridgeAges 18 years+ - NCT07616310Recruiting
Removing vs. Cutting Ovarian Cancer from the Bowel
This study compares two surgical approaches for removing advanced ovarian cancer that has attached to the rectosigmoid (lower bowel). Both methods aim to remove the cancer safely, but this trial tests whether one approach works as well as the other.
Hangzhou, ZhejiangAges 18–70
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian cancer?
- Yes. Clin2 currently lists 599 recruiting ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.